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Clinical review
Science, medicine, and the future
Cirrhosis: new research provides a basis for rational and
targeted treatments
John P Iredale
Liver transplantation and antiviral treatments for hepatitis have improved the outlook for many
patients with liver disease. For patients with cirrhosis, new developments herald targeted treatments
It is an exciting time to be working in hepatology. The
success of liver transplantation and the advances in the
radiological and endoscopic management of portal
hypertension have improved the longevity and quality
of life of patients with liver cirrhosis. Additionally, the
development of effective antiviral treatments means
that disease can be cured in many patients infected
with hepatitis B and hepatitis C. However, these
interventions also serve to highlight our current impo-
tence in altering the underlying fibrotic process in
many patients with liver disease. This rather depressing
perspective may soon change: data from clinical and
laboratory based research are showing that cirrhosis
may be reversible. By highlighting the attributes
required of an effective antifibrotic, a new dynamic
model is likely to lead to the development of targeted
treatment for liver cirrhosis.
Methods
This article is based on knowledge accrued over 13
years of work investigating the mechanisms of fibrosis
and aspects of hepatic stellate cell biology and on
regular Medline searches of the peer reviewed
scientific literature during that time. The field has
benefited from the recognition that certain mecha-
nisms are common to hepatic, renal, and pulmonary
fibrosis, and I have reviewed models of these pro-
cesses while preparing this article. My examples high-
light how laboratory based studies of the biology
of hepatic fibrosis may inform the design of future
treatments.
Clinical impact of cirrhosis
Liver fibrosis and its end stage, cirrhosis, represent
enormous worldwide healthcare problems. In the
United Kingdom, more than two thirds of the 4000
people who died of cirrhosis in 1999 were under 65,
and the incidence of cirrhosis related death is increas-
ing.1 Worldwide, the common causes of liver fibrosis
and cirrhosis include hepatitis B and hepatitis C and
alcohol. Other causes include immune mediated dam-
age, genetic abnormalities, and non-alcoholic steato-
hepatitis, which is associated with diabetes and the
metabolic syndrome.2 Changing patterns of alcohol
consumption in the West and the increasing rates of
obesity and diabetes mean that advances in preventing
and treating viral hepatitis may be offset by an increas-
ing burden of fibrosis and cirrhosis related to alcohol
and non-alcoholic steatohepatitis.1–3
Current treatments for cirrhosis are limited to
removing the underlying injurious stimulus (where
possible); eradicating viruses using interferon, riba-
virin, and lamivudine in viral hepatitis; and liver trans-
plantation. Transplantation is a highly successful
treatment for end stage cirrhosis, with a 75% five year
survival rate. But limited availability of organs, growing
lists of patients needing a transplant, issues of compat-
ibility, and comorbid factors mean that not everyone is
eligible for transplantation. As a result, effective anti-
fibrotic treatments are needed urgently.
Summary points
Fibrosis, the liver’s wound healing response, is
bi-directional and potentially reversible
Antiviral treatments provide increasing evidence
for reversibility of fibrosis and cirrhosis
Excess fibrillar (scar) matrix can be degraded even
in advanced cirrhosis but is held in check by
protease inhibitors termed TIMPs
Antifibrotic treatments are likely to be
developed in the next decade, on the basis of a
better understanding of the pathogenesis of
fibrosis
Hepatic stellate cells have been shown to
contribute to portal hypertension by dynamic
contractile activity; this could lead to the
design of specific agents to reduce portal
hypertension
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Inflammation and repair
Liver fibrosis and cirrhosis represent a continuous dis-
ease spectrum characterised by an increase in total
liver collagen and other matrix proteins which disrupt
the architecture of the liver and impair liver function.4 5
Fibrosis results from sustained wound healing in the
liver in response to chronic or iterative injury. The
wound healing response is an integral part of the over-
all process of inflammation and repair: it is dynamic
and has the potential to resolve without scarring (fig 1).
Pathogenesis of fibrosis
High quality experimental evidence supports the
hypothesis that the final common pathway of fibrosis is
mediated by the hepatic stellate cells.4–7 Hepatic stellate
cells in normal liver store retinoids and reside in the
spaces of Disse (fig 2). In injured areas of the liver,
hepatic stellate cells undergo a remarkable transforma-
tion: they resemble myofibroblasts and express
contractile proteins. In this “activated” phenotype,
hepatic stellate cells proliferate and are known to be
the major source of the fibrillar collagens that charac-
terise fibrosis and cirrhosis (fig 2). The mechanisms
mediating activation of hepatic stellate cells are a major
subject of research.
In injured areas, soluble factors (cytokines) are
released by the incoming inflammatory cells, the dam-
aged and regenerating hepatocytes, and other liver
cells that target the hepatic stellate cells, activating
them so they become the central mediators of wound
healing.5 Because of the key role of inflammation,
removing the causative agent and treating the patient
with immunosuppressive drugs are effective interven-
tions for some diseases (box). Greater understanding of
the specific cytokine and chemokine messengers that
mediate the inflammatory process in liver disease is
informing the design of future treatments. This is
exemplified by the identification of interleukin-10 as a
downregulator of the inflammatory response and
tumour necrosis factor  as a pro-inflammatory
mediator.8 9 Studies using interleukin-10 knockout
mice have identified this cytokine as a major
anti-inflammatory effector in fibrotic liver injury. A
pilot study suggested that interleukin-10 may be
valuable clinically in the context of hepatitis C virus
infection,10 but definitive evidence of efficacy has yet to
be produced in a large scale clinical trial. Antagonising
tumour necrosis factor  would also be expected to
downregulate hepatic inflammation. Reagents to
neutralise tumour necrosis factor  are available for
clinical use, and this approach is likely to be
investigated further in the clinic.11
Another approach to chronic liver fibrosis is to
block the signals which promote transition of hepatic
stellate cells from a quiescent to an activated
phenotype and promote collagen secretion. Foremost
among the soluble mediators promoting the fibro-
genic response from hepatic stellate cells is transform-
ing growth factor -1 (box). This cytokine also has a
role in the development of fibrosis in other organs,
including the lung and kidney.12 13 The activated
hepatic stellate cells respond to it by increasing
production of collagen and decreasing its breakdown
(see below). Models in other internal organs suggest
that modifying the secretion or activity of transforming
growth factor -1 can attenuate fibrosis, which
indicates that this is a possible antifibrotic target in the
liver.14 Recent studies of experimental liver fibrosis
have shown the potential of this approach.15
Matrix synthesis and turnover in fibrosis
and cirrhosis
Activated stellate cells proliferate, with the result that
increases in numbers of hepatic stellate cells, in
addition to increases in secretion of the fibrillar (or
Normal liver Inflamed Fibrotic liver Cirrhotic liver
Resolution Remodelling of cirrhosis
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Fig 1 Liver cirrhosis as wound healing: damage to the normal liver (a) results in
inflammation (b) and activation of hepatic stellate cells (brown) to secrete collagen,
culminating in the development of fibrosis (c) and ultimately in cirrhosis (d). Withdrawal of
the injurious agent may allow remodelling of the fibrillar matrix, leaving an attenuated
cirrhosis (e). Spontaneous resolution of fibrosis after removal of injury results in a return to
near normal architecture (f). Whether “complete” resolution of cirrhosis can occur is
currently unknown
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Fig 2 Normal liver (top) and liver injury (bottom). After livery injury, hepatic stellate cells
become activated and secrete a collagen rich matrix. Through associated changes in
cell-matrix interactions, hepatocytes lose their microvillii and sinusoidal endothelial cells lose
their fenestrations. Reproduced with permission26
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scarring) collagens, result in the deposition of excess
fibrotic matrix. Collagen synthesis is therefore clearly a
target for therapeutic intervention.16 Because fibrosis is
advanced when most patients present, understanding
the processes regulating matrix degradation is likely to
be pivotal to the development of effective anti-fibrotic
treatments. Effective treatment will require breakdown
of the pre-existing matrix.
Stellate cells and other cells involved in the fibrotic
process, including macrophages and Kupffer cells,
secrete a repertoire of matrix degrading metallo-
proteinase enzymes (MMPs).17 These enzymes degrade
collagen and other matrix molecules, and their
presence in the fibrotic liver highlights the potential
dynamic nature of scarring within the liver. Molecular
studies of the expression of mRNA for these enzymes
(including those with collagenolytic activity) have
shown that they are expressed in the liver even in
cirrhosis, but their activity is held in check by powerful
inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs) 1 and 2.18 The potential for matrix degra-
dation is present, even in advanced cirrhosis—but it is
held in check by concurrently secreted TIMPs (fig 3). It
should be possible to unharness the latent matrix
degrading capacity of a fibrotic or cirrhotic liver and to
facilitate matrix degradation, resulting in a return to
normal or near normal architecture.19
Models of resolution of liver fibrosis
Studies that used pathological specimens and paired
biopsies from trials of antiviral treatments in chronic
hepatitis have shown that matrix degradation occurs in
advanced human cirrhosis. In parallel, rodent models
in which spontaneous recovery from liver fibrosis and
cirrhosis occurs have allowed the frequent sampling
that is needed to identify the critical features of the
process.19–21 In recovery, expression of TIMPs 1 and 2
decreases rapidly while matrix degrading metallo-
proteinases continue to be expressed, resulting in
increased collagenase activity and consequent matrix
degradation within the liver (see fig 1).
Together with these changes, apoptosis of the
hepatic stellate cells occurs. Apoptosis, in effect the sui-
cide of a cell, fulfils a function in mammalian tissue,
removing unwanted cells when they become too
numerous or redundant. During progressive liver
injury, when stellate cells are activated in the normal
wound healing response, stellate cell apoptosis is fore-
stalled, probably through signals from soluble factors
and changes in the matrix. When the injurious
stimulus is withdrawn and remodelling of matrix is
required, the loss of these survival factors causes the
activated stellate cell to default into apoptosis, which
facilitates the remodelling process by removing the
major cellular source of collagen and TIMPs. Logically,
therefore, manipulating matrix degradation or
enhancing hepatic stellate cell apoptosis might be
expected to reduce fibrosis and promote a return to
normal liver architecture. Studies in this area are
currently limited to experimental models but show
promise that liver fibrosis can be attenuated by
manipulating the TIMP-MMP balance or enhancing
hepatic stellate cell apoptosis.22 23
Stellate cells as mediators of portal
hypertension
A major and life threatening consequence of cirrhosis
is the development of portal hypertension. Studies of
isolated hepatic stellate cells have revolutionised our
Possible therapeutic interventions in liver fibrosis
In progressive or established fibrosis
Inflammation
• Removal of injurious agent
• Interleukin-10—anti-inflammatory effect
• Tumour necrosis factor  inhibitors—anti-inflammatory effect
• Antioxidants—suppress fibrotic response to oxidative damage
Stellate cell activation
• Interferon gamma (or interferon alfa)—inhibits activation of hepatic
stellate cells
• Hepatocyte growth factor—inhibits activation of hepatic stellate cells
• Peroxisome proliferator-activated receptor ligand—reduces activation of
hepatic stellate cells
Perpetuation of stellate cell activation
• Transforming growth factor -1 antagonists—reduce matrix synthesis and
enhance matrix degradation
• Platelet derived growth factor antagonists—reduce proliferation of hepatic
stellate cells
• Nitric oxide—inhibits proliferation of hepatic stellate cells
• Angiotensin-converting-enzyme inhibitors—inhibit proliferation of
hepatic stellate cells
Stellate cell secretion of collagen rich matrix
• Angiotensin converting enzyme inhibitors—reduce fibrosis
• Polyhydroxylase inhibitors—reduce experimental fibrosis
• Interferon gamma—reduces fibrosis
• Endothelin receptor antagonists—reduce fibrosis and portal hypertension
To enhance or initiate resolution of fibrosis
Stellate cell apoptosis
• Gilotoxin—causes apoptosis of hepatic stellate cells
• Nerve growth factor—causes apoptosis of hepatic stellate cells
Degradation of collagen rich matrix
• Metalloproteinases—enhance activity of metalloproteinases
• Tissue inhibitor of matrix (TIMP) antagonists—enhance activity of
metalloproteinases
• Transforming growth factor -1 antagonists—downregulate TIMPs and
increases activity of metalloproteinases
• Relaxin—downregulates TIMPs and increases activity of metalloproteinases
Hepatic stellate
cell (HSC)
TIMP
  Collagen rich matrix
Matrix degrading metalloproteinase (MMP)
from HSC, Kupffer cell, or other inflammatory cell
MMP activity
inhibited; no matrix
degredation occurs
Activated hepatic stellate
cell (HSC) synthesises collagens I and III
and TIMPs 1 and 2
Fig 3 Tissue inhibitors of metalloproteinases (TIMPs) secreted by
activated hepatic stellate cells prevent matrix degradation by
inhibiting the enzymatic activity of matrix degrading
metalloproteinases (MMPs)
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view of the mechanisms underlying portal hyper-
tension and point to a role for these cells. Activation of
hepatic stellate cells is associated with the expression of
contractile intracellular proteins such as  smooth
muscle actin, and activated cells become sensitive to
the potent vasoactive substance endothelin. Endothe-
lin concentrations increase after fibrotic liver injury,
promoting contraction of hepatic stellate cells. In
parallel, injury results in a reduction in nitric oxide
derived from hepatic endothelial cells, which antago-
nises the effect of endothelin (fig 4). The net result of
this imbalance is that stellate cell contraction is stimu-
lated, and the consequent increases in intrahepatic
sinusoidal resistance contribute to portal hyper-
tension. The observation that this process is dynamic
and might be manipulated has led to the exciting con-
cept that effective endothelin antagonism might
reduce portal hypertension in cirrhosis.24
Serum markers of fibrosis
At present, the clinical assessment of antifibrotic inter-
ventions relies on serial liver biopsies. Liver biopsy
remains associated with a (small) morbidity and
mortality, and even though effective fibrosis scoring
systems have been introduced, liver biopsy is prone to
sampling error. It may not be an appropriate way of
monitoring in a dynamic situation such as a clinical
trial of an antifibrotic agent. A further likely
development is the identification of a panel of serum
fibrosis markers which can be used to predict the stage
of fibrosis and monitor disease progression or
resolution without recourse to repeated liver biopsies.25
The future
In future, patients with cirrhosis are likely to be treated
simultaneously with a targeted anti-inflammatory
agent, an agent to lower portal pressure, and an anti-
fibrotic or fibrolytic agent, and the effectiveness of the
treatment may well be monitored by using a panel of
serum markers. The development of effective targeted
treatments and the tools to monitor their effectiveness
non-invasively will change the way we view and treat
cirrhosis.
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Fig 4 Endothelin-nitric oxide imbalance results in contraction of
hepatic stellate cells, with consequent sinusoidal constriction
(indicated by yellow arrows), contributing to portal hypertension
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Lesson of the week
Interaction of spironolactone with ACE inhibitors or
angiotensin receptor blockers: analysis of 44 cases
Eike Wrenger, Regina Müller, Michael Moesenthin, Tobias Welte, Jürgen C Frölich,
Klaus H Neumann
The randomised aldactone evaluation study (RALES)
proved a substantial (30%) reduction in risk of
mortality in patients with severe congestive heart
failure by treatment with low dose spironolactone
(25-50 mg a day) in addition to standard treatment.1
Exclusion criteria for treatment in the study were a
plasma potassium concentration > 5.0 mmol/l and
serum creatinine concentration > 221 mol/l. A pilot
study had previously shown that the higher the dosage
of spironolactone (up to 24% with 75 mg a day) the
higher the risk of hyperkalaemia.2 Standard treatment
for patients with heart failure categorised as New York
Heart Association class II to IV includes angiotensin
converting enzyme (ACE) inhibitors or angiotensin II
AT1 receptor antagonists (AT1 receptor blockers).
3 Both
spironolactone and ACE inhibitors or AT1 receptor
blockers reduce the renal elimination of potassium.4 In
RALES, the increase in potassium was judged not to be
important as serious hyperkalaemia ( > 6 mmol/l)
occurred in only 10 (1%) of 841 patients taking
placebo and in 14 (2%) of 822 patients taking spironol-
actone, with no significant difference between the
groups. Discontinuation of the treatment was neces-
sary in only one patient taking placebo and three
patients taking spironolactone.1
We present a larger case series of life threatening
hyperkalaemia in patients who were receiving
spironolactone plus ACE inhibitors or AT1 receptor
blockers. We identify clinical circumstances associated
with this medical emergency and suggest recommen-
dations for prevention.
Case series
From January 1999 until December 2002 we observed
44 patients (17 men) with congestive heart failure who
were taking spironolactone and ACE inhibitors or AT1
receptor blockers and were admitted to our nephrol-
ogy unit (serving a population of about 250 000) for
treatment of life threatening hyperkalaemia. Their
mean age was 76 (standard deviation 11) years. The
mean dosage of spironolactone was 88 (SD 45, range
25-200) mg daily. All patients also received ACE
inhibitors or AT1 receptor blockers (table). Fourteen
patients were treated with  receptor blockers and 40
with loop diuretics.
Thirty five of the 44 patients had diabetes mellitus
type 2. Symptoms on admission were vomiting (19),
diarrhoea (8), bradyarrhythmia (14), muscle weakness
and paralysis (27), and severe dehydration (28). Mean
plasma potassium concentration on admission was 7.7
(SD 0.9, range 6.04-9.65) mmol/l and mean serum cre-
atinine concentration was 294 (SD 175, range 88-940
mol/l. Nineteen of the 44 patients had a serum creati-
nine concentration < 221 mol/l. Creatinine clear-
ance estimated by the formula of Cockroft and Gault5
was 0.38 (SD 0.22) ml/s and below the lower limit of
normal in all patients. Five patients had to be
resuscitated on admission. The figure shows electro-
cardiograms for patient 39, who on admission had a
serum potassium concentration of 9.65 mmol/l and,
after dialysis, had a lowered value of 4.65 mmol/l.
Haemodialysis was immediately started in 37
patients. Seven patients received conventional potas-
sium lowering treatment consisting of intravenous
sodium bicarbonate, intravenous furosemide (fruse-
mide), and intravenous glucose and insulin. The mean
number of dialysis treatments per patient was 2.5 (SD
1.2). However, in six patients renal function did not
recover, and they had to be kept on chronic dialysis
treatment. Two patients developed fatal complications
during their stay in the intensive care unit: a 75 year old
man died of gastrointestinal bleeding and an 88 year
old woman died of sepsis. Renal function recovered in
34 patients after closely monitored volume administra-
tion as dehydration was a common problem. At
discharge, creatinine clearance in the patients who
were not receiving dialysis was 0.65 (0.27) ml/s, with
serum creatinine values between 79 (SD 0.9) mol/l
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